author-photo

Oleg Gladkov

55

Papers

3868

Citations

Citation Trend

Filter By

Papers (37) Sort By

Journal Conference Others

OA01.03 Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Formation of Humic-Like Substances during the Technological Process of Lignohumate® Synthesis as a Function of Time

2021 Separations
Show All
- Source
- Cite
- Save
Citations (2)
P-121 Efficacy and toxicity of biosimilar and original bevacizumab in the second-line treatment of metastatic colon cancer in routine clinical practice: Results of an observational multicenter study

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥ 50%: EMPOWER-Lung 1 subgroup analysis.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Results of a completed first-in-human phase Ib dose-escalation study of oral CBL0137 in patients with advanced solid tumors.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Management of Muscle Invasive Bladder Cancer with Bladder Preservation in Russia: a Survey-Based Analysis of Current Practice and the Impact of an Educational Workshop on Clinical Expertise

2020 Journal of Cancer Education
Show All
- Source
- Cite
- Save
Citations (3)
Management of muscle-invasive bladder cancer with bladder preservation in Russia: A survey-based analysis of current practice and the impact of an educational workshop on clinical expertise.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy and safety of balugrastim in chemotherapy-induced neutropenia: Integrated analysis of two randomized phase III studies.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Phase II trial of huKS-IL2 with cyclophosphamide (CTX) in patients with extensive disease small-cell lung cancer (ED-SCLC).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.

2016 International Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (34)